Celyad - Model CYAD-221 - Allogeneic CAR T Candidate

CYAD-221 is a preclinical short hairpin RNA (shRNA)-based allogeneic CAR T candidate for the treatment of B-cell malignancies. CYAD-221 is engineered to co-express a CD19 chimeric antigen receptor and an shRNA hairpin which interferes with the expression of the CD3ζ component of the TCR complex.